Porcine vena cava as an alternative to bovine pericardium in bioprosthetic percutaneous heart valves
- PMID: 21993239
- PMCID: PMC3208764
- DOI: 10.1016/j.biomaterials.2011.09.027
Porcine vena cava as an alternative to bovine pericardium in bioprosthetic percutaneous heart valves
Abstract
Percutaneous heart valves are revolutionizing valve replacement surgery by offering a less invasive treatment option for high-risk patient populations who have previously been denied the traditional open chest procedure. Percutaneous valves need to be crimped to accommodate a small-diameter catheter during deployment, and they must then open to the size of heart valve. Thus the material used must be strong and possess elastic recoil for this application. Most percutaneous valves utilize bovine pericardium as a material of choice. One possible method to reduce the device delivery diameter is to utilize a thin, highly elastic tissue. Here we investigated porcine vena cava as an alternative to bovine pericardium for percutaneous valve application. We compared the structural, mechanical, and in vivo properties of porcine vena cava to those of bovine pericardium. While the extracellular matrix fibers of pericardium are randomly oriented, the vena cava contains highly aligned collagen and elastin fibers that impart strength to the vessel in the circumferential direction and elasticity in the longitudinal direction. Moreover, the vena cava contains a greater proportion of elastin, whereas the pericardium matrix is mainly composed of collagen. Due to its high elastin content, the vena cava is significantly less stiff than the pericardium, even after crosslinking with glutaraldehyde. Furthermore, the vena cava's mechanical compliance is preserved after compression under forces similar to those exerted by a stent, whereas pericardium is significantly stiffened by this process. Bovine pericardium also showed surface cracks observed by scanning electron microscopy after crimping that were not seen in vena cava tissue. Additionally, the vena cava exhibited reduced calcification (46.64 ± 8.15 μg Ca/mg tissue) as compared to the pericardium (86.79 ± 10.34 μg/mg). These results suggest that the vena cava may provide enhanced leaflet flexibility, tissue resilience, and tissue integrity in percutaneous heart valves, ultimately reducing the device profile while improving the durability of these valves.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Figures
Similar articles
-
Donkey pericardium compares favorably with commercial xenopericardia used in the manufacture of transcatheter heart valves.Artif Organs. 2019 Oct;43(10):976-987. doi: 10.1111/aor.13503. Epub 2019 Jul 3. Artif Organs. 2019. PMID: 31140630
-
Comparison of tensile properties of xenopericardium from three animal species and finite element analysis for bioprosthetic heart valve tissue.Artif Organs. 2020 Mar;44(3):278-287. doi: 10.1111/aor.13552. Epub 2019 Sep 1. Artif Organs. 2020. PMID: 31386771
-
Transcatheter heart valve crimping and the protecting effects of a polyester cuff.Morphologie. 2016 Dec;100(331):234-244. doi: 10.1016/j.morpho.2016.06.005. Epub 2016 Jul 22. Morphologie. 2016. PMID: 27461102
-
Mechanical considerations for polymeric heart valve development: Biomechanics, materials, design and manufacturing.Biomaterials. 2019 Dec;225:119493. doi: 10.1016/j.biomaterials.2019.119493. Epub 2019 Sep 17. Biomaterials. 2019. PMID: 31569017 Free PMC article. Review.
-
Long-Term Stability and Biocompatibility of Pericardial Bioprosthetic Heart Valves.Front Cardiovasc Med. 2021 Sep 13;8:728577. doi: 10.3389/fcvm.2021.728577. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34589529 Free PMC article. Review.
Cited by
-
Inhibition of advanced glycation end product formation and serum protein infiltration in bioprosthetic heart valve leaflets: Investigations of anti-glycation agents and anticalcification interactions with ethanol pretreatment.Biomaterials. 2022 Oct;289:121782. doi: 10.1016/j.biomaterials.2022.121782. Epub 2022 Sep 6. Biomaterials. 2022. PMID: 36099713 Free PMC article.
-
Yak Pericardium as an Alternative Biomaterial for Transcatheter Heart Valves.Front Bioeng Biotechnol. 2021 Nov 8;9:766991. doi: 10.3389/fbioe.2021.766991. eCollection 2021. Front Bioeng Biotechnol. 2021. PMID: 34820366 Free PMC article.
-
Swim bladder-derived biomaterials: structures, compositions, properties, modifications, and biomedical applications.J Nanobiotechnology. 2024 Apr 17;22(1):186. doi: 10.1186/s12951-024-02449-w. J Nanobiotechnology. 2024. PMID: 38632585 Free PMC article. Review.
-
Crosslinking and functionalization of acellular patches via the self-assembly of copper@tea polyphenol nanoparticles.Regen Biomater. 2022 May 18;9:rbac030. doi: 10.1093/rb/rbac030. eCollection 2022. Regen Biomater. 2022. PMID: 35665201 Free PMC article.
-
Pulmonary Visceral Pleura Biomaterial: Elastin- and Collagen-Based Extracellular Matrix.Front Bioeng Biotechnol. 2022 Mar 30;10:796076. doi: 10.3389/fbioe.2022.796076. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35433658 Free PMC article.
References
-
- Schoen FJ, Levy RJ. Founder’s Award, 25th Annual Meeting of the Society for Biomaterials, perspectives. Providence, RI, April 28-May 2, 1999. Tissue heart valves: current challenges and future research perspectives. J Biomed Mater Res. 1999;47:439–65. - PubMed
-
- Culliford AT, Galloway AC, Colvin SB, Grossi EA, Baumann FG, Esposito R, et al. Aortic valve replacement for aortic stenosis in persons aged 80 years and over. Am J Cardiol. 1991;67:1256–60. - PubMed
-
- Kvidal P, Bergstrom R, Horte LG, Stahle E. Observed and relative survival after aortic valve replacement. J Am Coll Cardiol. 2000;35:747–56. - PubMed
-
- Pai RG, Kapoor N, Bansal RC, Varadarajan P. Malignant natural history of asymptomatic severe aortic stenosis: benefit of aortic valve replacement. Ann Thorac Surg. 2006;82:2116–22. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources